Global CAR-T Therapy in Haematological Malignancy Market Growth (Status and Outlook) 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “CAR-T Therapy in Haematological Malignancy Industry Forecast” looks at past sales and reviews total world CAR-T Therapy in Haematological Malignancy sales in 2022, providing a comprehensive analysis by region and market sector of projected CAR-T Therapy in Haematological Malignancy sales for 2023 through 2029. With CAR-T Therapy in Haematological Malignancy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR-T Therapy in Haematological Malignancy industry.
This Insight Report provides a comprehensive analysis of the global CAR-T Therapy in Haematological Malignancy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CAR-T Therapy in Haematological Malignancy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CAR-T Therapy in Haematological Malignancy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR-T Therapy in Haematological Malignancy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR-T Therapy in Haematological Malignancy.
The global CAR-T Therapy in Haematological Malignancy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for CAR-T Therapy in Haematological Malignancy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for CAR-T Therapy in Haematological Malignancy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for CAR-T Therapy in Haematological Malignancy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key CAR-T Therapy in Haematological Malignancy players cover Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics and Mustang Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of CAR-T Therapy in Haematological Malignancy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
LPI (LP Information)' newest research report, the “CAR-T Therapy in Haematological Malignancy Industry Forecast” looks at past sales and reviews total world CAR-T Therapy in Haematological Malignancy sales in 2022, providing a comprehensive analysis by region and market sector of projected CAR-T Therapy in Haematological Malignancy sales for 2023 through 2029. With CAR-T Therapy in Haematological Malignancy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR-T Therapy in Haematological Malignancy industry.
This Insight Report provides a comprehensive analysis of the global CAR-T Therapy in Haematological Malignancy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CAR-T Therapy in Haematological Malignancy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CAR-T Therapy in Haematological Malignancy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR-T Therapy in Haematological Malignancy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR-T Therapy in Haematological Malignancy.
The global CAR-T Therapy in Haematological Malignancy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for CAR-T Therapy in Haematological Malignancy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for CAR-T Therapy in Haematological Malignancy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for CAR-T Therapy in Haematological Malignancy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key CAR-T Therapy in Haematological Malignancy players cover Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics and Mustang Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of CAR-T Therapy in Haematological Malignancy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- Allogeneic
- Autologous
- Hospitals
- Cancer Research Centers
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Celgene (Juno Therapeutics)
- Novartis
- Gilead (Kite Pharma)
- Pfizer
- CARsgen Therapeutics
- Autolus Therapeutics
- Aurora BioPharma
- Sorrento Therapeutics
- Mustang Bio
- Bluebird Bio
- Collectis
- Allogene Therapeutics
- Celyad
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size 2018-2029
2.1.2 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 CAR-T Therapy in Haematological Malignancy Segment by Type
2.2.1 Allogeneic
2.2.2 Autologous
2.3 CAR-T Therapy in Haematological Malignancy Market Size by Type
2.3.1 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
2.4 CAR-T Therapy in Haematological Malignancy Segment by Application
2.4.1 Hospitals
2.4.2 Cancer Research Centers
2.4.3 Others
2.5 CAR-T Therapy in Haematological Malignancy Market Size by Application
2.5.1 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
3 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET SIZE BY PLAYER
3.1 CAR-T Therapy in Haematological Malignancy Market Size Market Share by Players
3.1.1 Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2018-2023)
3.1.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2018-2023)
3.2 Global CAR-T Therapy in Haematological Malignancy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY BY REGIONS
4.1 CAR-T Therapy in Haematological Malignancy Market Size by Regions (2018-2023)
4.2 Americas CAR-T Therapy in Haematological Malignancy Market Size Growth (2018-2023)
4.3 APAC CAR-T Therapy in Haematological Malignancy Market Size Growth (2018-2023)
4.4 Europe CAR-T Therapy in Haematological Malignancy Market Size Growth (2018-2023)
4.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023)
5.2 Americas CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023)
5.3 Americas CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CAR-T Therapy in Haematological Malignancy Market Size by Region (2018-2023)
6.2 APAC CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023)
6.3 APAC CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe CAR-T Therapy in Haematological Malignancy by Country (2018-2023)
7.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023)
7.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy by Region (2018-2023)
8.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023)
8.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET FORECAST
10.1 Global CAR-T Therapy in Haematological Malignancy Forecast by Regions (2024-2029)
10.1.1 Global CAR-T Therapy in Haematological Malignancy Forecast by Regions (2024-2029)
10.1.2 Americas CAR-T Therapy in Haematological Malignancy Forecast
10.1.3 APAC CAR-T Therapy in Haematological Malignancy Forecast
10.1.4 Europe CAR-T Therapy in Haematological Malignancy Forecast
10.1.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Forecast
10.2 Americas CAR-T Therapy in Haematological Malignancy Forecast by Country (2024-2029)
10.2.1 United States CAR-T Therapy in Haematological Malignancy Market Forecast
10.2.2 Canada CAR-T Therapy in Haematological Malignancy Market Forecast
10.2.3 Mexico CAR-T Therapy in Haematological Malignancy Market Forecast
10.2.4 Brazil CAR-T Therapy in Haematological Malignancy Market Forecast
10.3 APAC CAR-T Therapy in Haematological Malignancy Forecast by Region (2024-2029)
10.3.1 China CAR-T Therapy in Haematological Malignancy Market Forecast
10.3.2 Japan CAR-T Therapy in Haematological Malignancy Market Forecast
10.3.3 Korea CAR-T Therapy in Haematological Malignancy Market Forecast
10.3.4 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Forecast
10.3.5 India CAR-T Therapy in Haematological Malignancy Market Forecast
10.3.6 Australia CAR-T Therapy in Haematological Malignancy Market Forecast
10.4 Europe CAR-T Therapy in Haematological Malignancy Forecast by Country (2024-2029)
10.4.1 Germany CAR-T Therapy in Haematological Malignancy Market Forecast
10.4.2 France CAR-T Therapy in Haematological Malignancy Market Forecast
10.4.3 UK CAR-T Therapy in Haematological Malignancy Market Forecast
10.4.4 Italy CAR-T Therapy in Haematological Malignancy Market Forecast
10.4.5 Russia CAR-T Therapy in Haematological Malignancy Market Forecast
10.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Forecast by Region (2024-2029)
10.5.1 Egypt CAR-T Therapy in Haematological Malignancy Market Forecast
10.5.2 South Africa CAR-T Therapy in Haematological Malignancy Market Forecast
10.5.3 Israel CAR-T Therapy in Haematological Malignancy Market Forecast
10.5.4 Turkey CAR-T Therapy in Haematological Malignancy Market Forecast
10.5.5 GCC Countries CAR-T Therapy in Haematological Malignancy Market Forecast
10.6 Global CAR-T Therapy in Haematological Malignancy Forecast by Type (2024-2029)
10.7 Global CAR-T Therapy in Haematological Malignancy Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Celgene (Juno Therapeutics)
11.1.1 Celgene (Juno Therapeutics) Company Information
11.1.2 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Offered
11.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Celgene (Juno Therapeutics) Main Business Overview
11.1.5 Celgene (Juno Therapeutics) Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis CAR-T Therapy in Haematological Malignancy Product Offered
11.2.3 Novartis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Gilead (Kite Pharma)
11.3.1 Gilead (Kite Pharma) Company Information
11.3.2 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Offered
11.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Gilead (Kite Pharma) Main Business Overview
11.3.5 Gilead (Kite Pharma) Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer CAR-T Therapy in Haematological Malignancy Product Offered
11.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 CARsgen Therapeutics
11.5.1 CARsgen Therapeutics Company Information
11.5.2 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
11.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 CARsgen Therapeutics Main Business Overview
11.5.5 CARsgen Therapeutics Latest Developments
11.6 Autolus Therapeutics
11.6.1 Autolus Therapeutics Company Information
11.6.2 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
11.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Autolus Therapeutics Main Business Overview
11.6.5 Autolus Therapeutics Latest Developments
11.7 Aurora BioPharma
11.7.1 Aurora BioPharma Company Information
11.7.2 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Offered
11.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Aurora BioPharma Main Business Overview
11.7.5 Aurora BioPharma Latest Developments
11.8 Sorrento Therapeutics
11.8.1 Sorrento Therapeutics Company Information
11.8.2 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
11.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Sorrento Therapeutics Main Business Overview
11.8.5 Sorrento Therapeutics Latest Developments
11.9 Mustang Bio
11.9.1 Mustang Bio Company Information
11.9.2 Mustang Bio CAR-T Therapy in Haematological Malignancy Product Offered
11.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Mustang Bio Main Business Overview
11.9.5 Mustang Bio Latest Developments
11.10 Bluebird Bio
11.10.1 Bluebird Bio Company Information
11.10.2 Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Offered
11.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Bluebird Bio Main Business Overview
11.10.5 Bluebird Bio Latest Developments
11.11 Collectis
11.11.1 Collectis Company Information
11.11.2 Collectis CAR-T Therapy in Haematological Malignancy Product Offered
11.11.3 Collectis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Collectis Main Business Overview
11.11.5 Collectis Latest Developments
11.12 Allogene Therapeutics
11.12.1 Allogene Therapeutics Company Information
11.12.2 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
11.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Allogene Therapeutics Main Business Overview
11.12.5 Allogene Therapeutics Latest Developments
11.13 Celyad
11.13.1 Celyad Company Information
11.13.2 Celyad CAR-T Therapy in Haematological Malignancy Product Offered
11.13.3 Celyad CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Celyad Main Business Overview
11.13.5 Celyad Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size 2018-2029
2.1.2 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 CAR-T Therapy in Haematological Malignancy Segment by Type
2.2.1 Allogeneic
2.2.2 Autologous
2.3 CAR-T Therapy in Haematological Malignancy Market Size by Type
2.3.1 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
2.4 CAR-T Therapy in Haematological Malignancy Segment by Application
2.4.1 Hospitals
2.4.2 Cancer Research Centers
2.4.3 Others
2.5 CAR-T Therapy in Haematological Malignancy Market Size by Application
2.5.1 CAR-T Therapy in Haematological Malignancy Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
3 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET SIZE BY PLAYER
3.1 CAR-T Therapy in Haematological Malignancy Market Size Market Share by Players
3.1.1 Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2018-2023)
3.1.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2018-2023)
3.2 Global CAR-T Therapy in Haematological Malignancy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY BY REGIONS
4.1 CAR-T Therapy in Haematological Malignancy Market Size by Regions (2018-2023)
4.2 Americas CAR-T Therapy in Haematological Malignancy Market Size Growth (2018-2023)
4.3 APAC CAR-T Therapy in Haematological Malignancy Market Size Growth (2018-2023)
4.4 Europe CAR-T Therapy in Haematological Malignancy Market Size Growth (2018-2023)
4.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023)
5.2 Americas CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023)
5.3 Americas CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CAR-T Therapy in Haematological Malignancy Market Size by Region (2018-2023)
6.2 APAC CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023)
6.3 APAC CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe CAR-T Therapy in Haematological Malignancy by Country (2018-2023)
7.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023)
7.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy by Region (2018-2023)
8.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023)
8.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET FORECAST
10.1 Global CAR-T Therapy in Haematological Malignancy Forecast by Regions (2024-2029)
10.1.1 Global CAR-T Therapy in Haematological Malignancy Forecast by Regions (2024-2029)
10.1.2 Americas CAR-T Therapy in Haematological Malignancy Forecast
10.1.3 APAC CAR-T Therapy in Haematological Malignancy Forecast
10.1.4 Europe CAR-T Therapy in Haematological Malignancy Forecast
10.1.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Forecast
10.2 Americas CAR-T Therapy in Haematological Malignancy Forecast by Country (2024-2029)
10.2.1 United States CAR-T Therapy in Haematological Malignancy Market Forecast
10.2.2 Canada CAR-T Therapy in Haematological Malignancy Market Forecast
10.2.3 Mexico CAR-T Therapy in Haematological Malignancy Market Forecast
10.2.4 Brazil CAR-T Therapy in Haematological Malignancy Market Forecast
10.3 APAC CAR-T Therapy in Haematological Malignancy Forecast by Region (2024-2029)
10.3.1 China CAR-T Therapy in Haematological Malignancy Market Forecast
10.3.2 Japan CAR-T Therapy in Haematological Malignancy Market Forecast
10.3.3 Korea CAR-T Therapy in Haematological Malignancy Market Forecast
10.3.4 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Forecast
10.3.5 India CAR-T Therapy in Haematological Malignancy Market Forecast
10.3.6 Australia CAR-T Therapy in Haematological Malignancy Market Forecast
10.4 Europe CAR-T Therapy in Haematological Malignancy Forecast by Country (2024-2029)
10.4.1 Germany CAR-T Therapy in Haematological Malignancy Market Forecast
10.4.2 France CAR-T Therapy in Haematological Malignancy Market Forecast
10.4.3 UK CAR-T Therapy in Haematological Malignancy Market Forecast
10.4.4 Italy CAR-T Therapy in Haematological Malignancy Market Forecast
10.4.5 Russia CAR-T Therapy in Haematological Malignancy Market Forecast
10.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Forecast by Region (2024-2029)
10.5.1 Egypt CAR-T Therapy in Haematological Malignancy Market Forecast
10.5.2 South Africa CAR-T Therapy in Haematological Malignancy Market Forecast
10.5.3 Israel CAR-T Therapy in Haematological Malignancy Market Forecast
10.5.4 Turkey CAR-T Therapy in Haematological Malignancy Market Forecast
10.5.5 GCC Countries CAR-T Therapy in Haematological Malignancy Market Forecast
10.6 Global CAR-T Therapy in Haematological Malignancy Forecast by Type (2024-2029)
10.7 Global CAR-T Therapy in Haematological Malignancy Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Celgene (Juno Therapeutics)
11.1.1 Celgene (Juno Therapeutics) Company Information
11.1.2 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Offered
11.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Celgene (Juno Therapeutics) Main Business Overview
11.1.5 Celgene (Juno Therapeutics) Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis CAR-T Therapy in Haematological Malignancy Product Offered
11.2.3 Novartis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Gilead (Kite Pharma)
11.3.1 Gilead (Kite Pharma) Company Information
11.3.2 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Offered
11.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Gilead (Kite Pharma) Main Business Overview
11.3.5 Gilead (Kite Pharma) Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer CAR-T Therapy in Haematological Malignancy Product Offered
11.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 CARsgen Therapeutics
11.5.1 CARsgen Therapeutics Company Information
11.5.2 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
11.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 CARsgen Therapeutics Main Business Overview
11.5.5 CARsgen Therapeutics Latest Developments
11.6 Autolus Therapeutics
11.6.1 Autolus Therapeutics Company Information
11.6.2 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
11.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Autolus Therapeutics Main Business Overview
11.6.5 Autolus Therapeutics Latest Developments
11.7 Aurora BioPharma
11.7.1 Aurora BioPharma Company Information
11.7.2 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Offered
11.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Aurora BioPharma Main Business Overview
11.7.5 Aurora BioPharma Latest Developments
11.8 Sorrento Therapeutics
11.8.1 Sorrento Therapeutics Company Information
11.8.2 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
11.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Sorrento Therapeutics Main Business Overview
11.8.5 Sorrento Therapeutics Latest Developments
11.9 Mustang Bio
11.9.1 Mustang Bio Company Information
11.9.2 Mustang Bio CAR-T Therapy in Haematological Malignancy Product Offered
11.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Mustang Bio Main Business Overview
11.9.5 Mustang Bio Latest Developments
11.10 Bluebird Bio
11.10.1 Bluebird Bio Company Information
11.10.2 Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Offered
11.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Bluebird Bio Main Business Overview
11.10.5 Bluebird Bio Latest Developments
11.11 Collectis
11.11.1 Collectis Company Information
11.11.2 Collectis CAR-T Therapy in Haematological Malignancy Product Offered
11.11.3 Collectis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Collectis Main Business Overview
11.11.5 Collectis Latest Developments
11.12 Allogene Therapeutics
11.12.1 Allogene Therapeutics Company Information
11.12.2 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
11.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Allogene Therapeutics Main Business Overview
11.12.5 Allogene Therapeutics Latest Developments
11.13 Celyad
11.13.1 Celyad Company Information
11.13.2 Celyad CAR-T Therapy in Haematological Malignancy Product Offered
11.13.3 Celyad CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Celyad Main Business Overview
11.13.5 Celyad Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Allogeneic
Table 3. Major Players of Autologous
Table 4. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 5. Global CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & ($ Millions)
Table 6. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Table 7. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & ($ Millions)
Table 9. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Table 10. Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2018-2023) & ($ Millions)
Table 11. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Player (2018-2023)
Table 12. CAR-T Therapy in Haematological Malignancy Key Players Head office and Products Offered
Table 13. CAR-T Therapy in Haematological Malignancy Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions 2018-2023 & ($ Millions)
Table 17. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions (2018-2023)
Table 18. Global CAR-T Therapy in Haematological Malignancy Revenue by Country/Region (2018-2023) & ($ millions)
Table 19. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Country/Region (2018-2023)
Table 20. Americas CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023) & ($ Millions)
Table 21. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Country (2018-2023)
Table 22. Americas CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & ($ Millions)
Table 23. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Table 24. Americas CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & ($ Millions)
Table 25. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Table 26. APAC CAR-T Therapy in Haematological Malignancy Market Size by Region (2018-2023) & ($ Millions)
Table 27. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region (2018-2023)
Table 28. APAC CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & ($ Millions)
Table 29. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Table 30. APAC CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & ($ Millions)
Table 31. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Table 32. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023) & ($ Millions)
Table 33. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Country (2018-2023)
Table 34. Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & ($ Millions)
Table 35. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Table 36. Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & ($ Millions)
Table 37. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Table 38. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Region (2018-2023) & ($ Millions)
Table 39. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region (2018-2023)
Table 40. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & ($ Millions)
Table 41. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Table 42. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & ($ Millions)
Table 43. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Table 44. Key Market Drivers & Growth Opportunities of CAR-T Therapy in Haematological Malignancy
Table 45. Key Market Challenges & Risks of CAR-T Therapy in Haematological Malignancy
Table 46. Key Industry Trends of CAR-T Therapy in Haematological Malignancy
Table 47. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 48. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Regions (2024-2029)
Table 49. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 50. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 51. Celgene (Juno Therapeutics) Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 52. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Offered
Table 53. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 54. Celgene (Juno Therapeutics) Main Business
Table 55. Celgene (Juno Therapeutics) Latest Developments
Table 56. Novartis Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 57. Novartis CAR-T Therapy in Haematological Malignancy Product Offered
Table 58. Novartis Main Business
Table 59. Novartis CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 60. Novartis Latest Developments
Table 61. Gilead (Kite Pharma) Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 62. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Offered
Table 63. Gilead (Kite Pharma) Main Business
Table 64. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. Gilead (Kite Pharma) Latest Developments
Table 66. Pfizer Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 67. Pfizer CAR-T Therapy in Haematological Malignancy Product Offered
Table 68. Pfizer Main Business
Table 69. Pfizer CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. Pfizer Latest Developments
Table 71. CARsgen Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 72. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
Table 73. CARsgen Therapeutics Main Business
Table 74. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. CARsgen Therapeutics Latest Developments
Table 76. Autolus Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 77. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
Table 78. Autolus Therapeutics Main Business
Table 79. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. Autolus Therapeutics Latest Developments
Table 81. Aurora BioPharma Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 82. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Offered
Table 83. Aurora BioPharma Main Business
Table 84. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 85. Aurora BioPharma Latest Developments
Table 86. Sorrento Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 87. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
Table 88. Sorrento Therapeutics Main Business
Table 89. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 90. Sorrento Therapeutics Latest Developments
Table 91. Mustang Bio Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 92. Mustang Bio CAR-T Therapy in Haematological Malignancy Product Offered
Table 93. Mustang Bio Main Business
Table 94. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 95. Mustang Bio Latest Developments
Table 96. Bluebird Bio Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 97. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Offered
Table 98. Bluebird Bio Main Business
Table 99. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 100. Bluebird Bio Latest Developments
Table 101. Collectis Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 102. Collectis CAR-T Therapy in Haematological Malignancy Product Offered
Table 103. Collectis CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 104. Collectis Main Business
Table 105. Collectis Latest Developments
Table 106. Allogene Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 107. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
Table 108. Allogene Therapeutics Main Business
Table 109. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 110. Allogene Therapeutics Latest Developments
Table 111. Celyad Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 112. Celyad CAR-T Therapy in Haematological Malignancy Product Offered
Table 113. Celyad Main Business
Table 114. Celyad CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 115. Celyad Latest Developments
Table 1. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Allogeneic
Table 3. Major Players of Autologous
Table 4. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 5. Global CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & ($ Millions)
Table 6. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Table 7. CAR-T Therapy in Haematological Malignancy Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & ($ Millions)
Table 9. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Table 10. Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2018-2023) & ($ Millions)
Table 11. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Player (2018-2023)
Table 12. CAR-T Therapy in Haematological Malignancy Key Players Head office and Products Offered
Table 13. CAR-T Therapy in Haematological Malignancy Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions 2018-2023 & ($ Millions)
Table 17. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions (2018-2023)
Table 18. Global CAR-T Therapy in Haematological Malignancy Revenue by Country/Region (2018-2023) & ($ millions)
Table 19. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Country/Region (2018-2023)
Table 20. Americas CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023) & ($ Millions)
Table 21. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Country (2018-2023)
Table 22. Americas CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & ($ Millions)
Table 23. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Table 24. Americas CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & ($ Millions)
Table 25. Americas CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Table 26. APAC CAR-T Therapy in Haematological Malignancy Market Size by Region (2018-2023) & ($ Millions)
Table 27. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region (2018-2023)
Table 28. APAC CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & ($ Millions)
Table 29. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Table 30. APAC CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & ($ Millions)
Table 31. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Table 32. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023) & ($ Millions)
Table 33. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Country (2018-2023)
Table 34. Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & ($ Millions)
Table 35. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Table 36. Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & ($ Millions)
Table 37. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Table 38. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Region (2018-2023) & ($ Millions)
Table 39. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region (2018-2023)
Table 40. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & ($ Millions)
Table 41. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Table 42. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & ($ Millions)
Table 43. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Table 44. Key Market Drivers & Growth Opportunities of CAR-T Therapy in Haematological Malignancy
Table 45. Key Market Challenges & Risks of CAR-T Therapy in Haematological Malignancy
Table 46. Key Industry Trends of CAR-T Therapy in Haematological Malignancy
Table 47. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 48. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Regions (2024-2029)
Table 49. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 50. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 51. Celgene (Juno Therapeutics) Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 52. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Offered
Table 53. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 54. Celgene (Juno Therapeutics) Main Business
Table 55. Celgene (Juno Therapeutics) Latest Developments
Table 56. Novartis Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 57. Novartis CAR-T Therapy in Haematological Malignancy Product Offered
Table 58. Novartis Main Business
Table 59. Novartis CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 60. Novartis Latest Developments
Table 61. Gilead (Kite Pharma) Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 62. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Offered
Table 63. Gilead (Kite Pharma) Main Business
Table 64. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. Gilead (Kite Pharma) Latest Developments
Table 66. Pfizer Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 67. Pfizer CAR-T Therapy in Haematological Malignancy Product Offered
Table 68. Pfizer Main Business
Table 69. Pfizer CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. Pfizer Latest Developments
Table 71. CARsgen Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 72. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
Table 73. CARsgen Therapeutics Main Business
Table 74. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. CARsgen Therapeutics Latest Developments
Table 76. Autolus Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 77. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
Table 78. Autolus Therapeutics Main Business
Table 79. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. Autolus Therapeutics Latest Developments
Table 81. Aurora BioPharma Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 82. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Offered
Table 83. Aurora BioPharma Main Business
Table 84. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 85. Aurora BioPharma Latest Developments
Table 86. Sorrento Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 87. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
Table 88. Sorrento Therapeutics Main Business
Table 89. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 90. Sorrento Therapeutics Latest Developments
Table 91. Mustang Bio Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 92. Mustang Bio CAR-T Therapy in Haematological Malignancy Product Offered
Table 93. Mustang Bio Main Business
Table 94. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 95. Mustang Bio Latest Developments
Table 96. Bluebird Bio Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 97. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Offered
Table 98. Bluebird Bio Main Business
Table 99. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 100. Bluebird Bio Latest Developments
Table 101. Collectis Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 102. Collectis CAR-T Therapy in Haematological Malignancy Product Offered
Table 103. Collectis CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 104. Collectis Main Business
Table 105. Collectis Latest Developments
Table 106. Allogene Therapeutics Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 107. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Offered
Table 108. Allogene Therapeutics Main Business
Table 109. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 110. Allogene Therapeutics Latest Developments
Table 111. Celyad Details, Company Type, CAR-T Therapy in Haematological Malignancy Area Served and Its Competitors
Table 112. Celyad CAR-T Therapy in Haematological Malignancy Product Offered
Table 113. Celyad Main Business
Table 114. Celyad CAR-T Therapy in Haematological Malignancy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 115. Celyad Latest Developments
LIST OF FIGURES
Figure 1. CAR-T Therapy in Haematological Malignancy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. CAR-T Therapy in Haematological Malignancy Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. CAR-T Therapy in Haematological Malignancy Sales Market Share by Country/Region (2022)
Figure 8. CAR-T Therapy in Haematological Malignancy Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2022
Figure 10. CAR-T Therapy in Haematological Malignancy in Hospitals
Figure 11. Global CAR-T Therapy in Haematological Malignancy Market: Hospitals (2018-2023) & ($ Millions)
Figure 12. CAR-T Therapy in Haematological Malignancy in Cancer Research Centers
Figure 13. Global CAR-T Therapy in Haematological Malignancy Market: Cancer Research Centers (2018-2023) & ($ Millions)
Figure 14. CAR-T Therapy in Haematological Malignancy in Others
Figure 15. Global CAR-T Therapy in Haematological Malignancy Market: Others (2018-2023) & ($ Millions)
Figure 16. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2022
Figure 17. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Player in 2022
Figure 18. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions (2018-2023)
Figure 19. Americas CAR-T Therapy in Haematological Malignancy Market Size 2018-2023 ($ Millions)
Figure 20. APAC CAR-T Therapy in Haematological Malignancy Market Size 2018-2023 ($ Millions)
Figure 21. Europe CAR-T Therapy in Haematological Malignancy Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size 2018-2023 ($ Millions)
Figure 23. Americas CAR-T Therapy in Haematological Malignancy Value Market Share by Country in 2022
Figure 24. United States CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region in 2022
Figure 29. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2022
Figure 30. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2022
Figure 31. China CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 35. India CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Country in 2022
Figure 38. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Figure 39. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Figure 40. Germany CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 41. France CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Figure 48. Egypt CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 54. APAC CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 55. Europe CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 57. United States CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 58. Canada CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 59. Mexico CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 60. Brazil CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 61. China CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 62. Japan CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 63. Korea CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 65. India CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 66. Australia CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 67. Germany CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 68. France CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 69. UK CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 70. Italy CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 71. Russia CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 72. Spain CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 73. Egypt CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 74. South Africa CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 75. Israel CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 76. Turkey CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 78. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Application (2024-2029)
Figure 1. CAR-T Therapy in Haematological Malignancy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. CAR-T Therapy in Haematological Malignancy Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. CAR-T Therapy in Haematological Malignancy Sales Market Share by Country/Region (2022)
Figure 8. CAR-T Therapy in Haematological Malignancy Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2022
Figure 10. CAR-T Therapy in Haematological Malignancy in Hospitals
Figure 11. Global CAR-T Therapy in Haematological Malignancy Market: Hospitals (2018-2023) & ($ Millions)
Figure 12. CAR-T Therapy in Haematological Malignancy in Cancer Research Centers
Figure 13. Global CAR-T Therapy in Haematological Malignancy Market: Cancer Research Centers (2018-2023) & ($ Millions)
Figure 14. CAR-T Therapy in Haematological Malignancy in Others
Figure 15. Global CAR-T Therapy in Haematological Malignancy Market: Others (2018-2023) & ($ Millions)
Figure 16. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2022
Figure 17. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Player in 2022
Figure 18. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Regions (2018-2023)
Figure 19. Americas CAR-T Therapy in Haematological Malignancy Market Size 2018-2023 ($ Millions)
Figure 20. APAC CAR-T Therapy in Haematological Malignancy Market Size 2018-2023 ($ Millions)
Figure 21. Europe CAR-T Therapy in Haematological Malignancy Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size 2018-2023 ($ Millions)
Figure 23. Americas CAR-T Therapy in Haematological Malignancy Value Market Share by Country in 2022
Figure 24. United States CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region in 2022
Figure 29. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type in 2022
Figure 30. APAC CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application in 2022
Figure 31. China CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 35. India CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Country in 2022
Figure 38. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Figure 39. Europe CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Figure 40. Germany CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 41. France CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Market Share by Application (2018-2023)
Figure 48. Egypt CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country CAR-T Therapy in Haematological Malignancy Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 54. APAC CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 55. Europe CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 57. United States CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 58. Canada CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 59. Mexico CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 60. Brazil CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 61. China CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 62. Japan CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 63. Korea CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 65. India CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 66. Australia CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 67. Germany CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 68. France CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 69. UK CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 70. Italy CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 71. Russia CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 72. Spain CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 73. Egypt CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 74. South Africa CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 75. Israel CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 76. Turkey CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries CAR-T Therapy in Haematological Malignancy Market Size 2024-2029 ($ Millions)
Figure 78. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global CAR-T Therapy in Haematological Malignancy Market Size Market Share Forecast by Application (2024-2029)
